The US Food and Drug Administration (FDA) of the United States has approved Janssen Pharmaceutical’s IMBRUVICA for the treatment of pediatric patients one year and older suffering with chronic graft-versus-host disease after the failure of more than one therapy. Janssen claims that, this milestone marks the first pediatric indication for IMBRUVICA, and the launch of […]
Continue Reading
A total of 100,000 doses of the Janssen COVID-19 vaccine were delivered to Ukraine in August 2022 under the COVAX initiative, and have been distributed to 22 regions in the country by the Ministry of Health. Dr. Jarno Habicht, WHO representative in Ukraine, said these vaccines will further provide protection against COVID-19, and they are […]
Continue Reading
The US Food and Drug Administration (FDA) has approved STELARA produced by Janssen Pharmaceutical Company of Johnson & Johnson, for the treatment of pediatric patients older than six years with active psoriatic arthritis (PsA). This rare disease affects around 8 percent of children and adolescents with chronic inflammatory arthritis. STELARA is a fully human monoclonal […]
Continue Reading